Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of TAK-385 together with leuprorelin in prostate cancer has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprorelin (leuprorelin)
• TAK-385

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-05-09